|
aflibercept |
1 |
|
alternate splicing |
1 |
|
alternative possibility, and cross-species identification - spectral libraries and profiles |
1 |
|
anti-vascular endothelial growth factor |
1 |
|
bevacizumab |
1 |
|
bioinformatics |
1 |
|
bioinformatics in animal proteomics - methodologies, analyzing protein sets in complex samples |
1 |
|
biomarker |
1 |
|
cell transplantation |
1 |
|
diabetic macular edema |
1 |
|
difficulties of applying proteomics - and next-generation sequencing, in easing problems |
1 |
|
dna damage response |
1 |
|
embryonic stem cells |
1 |
|
epiblast |
1 |
|
expressed sequence tag |
1 |
|
extraembryonic endoderm |
1 |
|
false discovery rate |
1 |
|
gata6 |
1 |
|
genome sequencing, acceleration - new technological developments, "next-generation" sequencers |
1 |
|
h3k9me3 |
1 |
|
human |
1 |
|
human embryonic stem cells |
1 |
|
intron-spanning peptides, unique to specific protein - in proteomic analysis of alternative splicing |
1 |
|
meiotic silencing |
1 |
|
microrna |
1 |
|
mouse |
1 |
|
mouse embryonic stem cells |
1 |
|
msci |
1 |
|
peptide identifications |
1 |
|
peptide spectrum match |
1 |
|
pluripotency |
1 |
|
pluripotent stem cell |
1 |
|
posterior error probability |
1 |
|
protein identification in proteomics - by ms, in a single stage |
1 |
|
protein isoforms |
1 |
|
proteogenomics |
1 |
|
proteomic analysis, using - one-dimensional gels, 2d gels and multidimensional protein identification technology [mudpit] |
1 |
|
proteomic data to genome annotation - "proteogenomics" |
1 |
|
proteomics analysis pipelines and data repositories - as genome annotating proteomics pipeline (gapp) and peptideatlas |
1 |
|
reprograming |
1 |
|
retinal pigment epithelium |
1 |
|
rna-sequencing |
1 |
|
sex chromosomes |
1 |
|
tandem ms, single peptide ion - from ms1 stage, fragmented prior to mass analysis in ms2 stage |
1 |
|
transcriptome |
1 |
|
trophectoderm |
1 |
